Regulus Therapeutics (NASDAQ:RGLS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research report sent to investors on Monday, Benzinga reports. HC Wainwright currently has a $9.00 price target on the biopharmaceutical company’s stock.

RGLS has been the topic of a number of other reports. Canaccord Genuity Group decreased their target price on Regulus Therapeutics from $12.00 to $11.00 and set a buy rating on the stock in a research report on Tuesday, March 19th. Leerink Partnrs reiterated an outperform rating on shares of Regulus Therapeutics in a research report on Monday, March 18th. SVB Leerink initiated coverage on shares of Regulus Therapeutics in a research report on Monday, March 18th. They issued an outperform rating and a $6.00 price target on the stock. Wells Fargo & Company increased their price objective on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the company an equal weight rating in a research report on Wednesday, March 13th. Finally, StockNews.com assumed coverage on shares of Regulus Therapeutics in a report on Tuesday, April 16th. They issued a sell rating on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average target price of $7.25.

Regulus Therapeutics Price Performance

Shares of RGLS opened at $2.27 on Monday. The firm has a market cap of $148.59 million, a P/E ratio of -1.43 and a beta of 1.59. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.79. The company has a 50 day simple moving average of $2.35 and a two-hundred day simple moving average of $1.70.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). On average, sell-side analysts anticipate that Regulus Therapeutics will post -0.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Victory Capital Management Inc. boosted its holdings in Regulus Therapeutics by 5.3% during the 3rd quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company’s stock valued at $322,000 after acquiring an additional 11,701 shares during the period. FMR LLC boosted its stake in shares of Regulus Therapeutics by 32.4% during the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after purchasing an additional 716,000 shares during the period. CVI Holdings LLC bought a new position in shares of Regulus Therapeutics in the first quarter worth about $4,050,000. Finally, Vivo Capital LLC purchased a new position in Regulus Therapeutics in the 1st quarter worth about $14,400,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.